The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in patients with lung cancer patients undergoing treatment with amivantamab and lazertinib.
Byoung Chul Cho, MD, PhD
Advertisement
Byoung Chul Cho, MD, PhD, is a medical oncologist at Yonsei Cancer Center in South Korea.
Articles by Byoung Chul Cho, MD, PhD
Byoung Chul Cho, MD, PhD, discusses the implications of the CHRYSALIS-2 study of amivantamab and lazertinib.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
